(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 181.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Nuvation Bio's revenue in 2025 is $10,957,000.On average, 3 Wall Street analysts forecast NUVB's revenue for 2025 to be $5,971,615,229, with the lowest NUVB revenue forecast at $5,536,078,620, and the highest NUVB revenue forecast at $6,662,349,070. On average, 3 Wall Street analysts forecast NUVB's revenue for 2026 to be $41,260,288,470, with the lowest NUVB revenue forecast at $29,228,589,638, and the highest NUVB revenue forecast at $54,979,691,662.
In 2027, NUVB is forecast to generate $87,709,587,324 in revenue, with the lowest revenue forecast at $87,709,587,324 and the highest revenue forecast at $87,709,587,324.